Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data

Stock Track04-29

Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.

The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a target price of HKD 298.28. The broker highlighted the company's robust generic drug business, which has delivered five consecutive years of profitability, with revenue reaching RMB 582 million (up 25% year-over-year) and net profit of RMB 177 million (up 30%).

Investor sentiment was further bolstered by positive updates on the company's innovation pipeline. Phase I clinical data for its novel oral drug HXP056, targeting fundus diseases, demonstrated favorable safety and tolerability, with preliminary signs of efficacy. Additionally, the company's most advanced candidate, C019199, is poised to enter Phase III clinical trials. This combination of validating broker coverage and promising pipeline catalysts supported the stock's technical rebound from a sharp decline in the previous session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119193958?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119193958","market":"nz","top_or_hot":-1,"title":"Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data","media":"Stock Track","content":"<p>Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.</p><p>The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a target price of HKD 298.28. The broker highlighted the company's robust generic drug business, which has delivered five consecutive years of profitability, with revenue reaching RMB 582 million (up 25% year-over-year) and net profit of RMB 177 million (up 30%).</p><p>Investor sentiment was further bolstered by positive updates on the company's innovation pipeline. Phase I clinical data for its novel oral drug HXP056, targeting fundus diseases, demonstrated favorable safety and tolerability, with preliminary signs of efficacy. Additionally, the company's most advanced candidate, C019199, is poised to enter Phase III clinical trials. This combination of validating broker coverage and promising pipeline catalysts supported the stock's technical rebound from a sharp decline in the previous session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.</p><p>The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a target price of HKD 298.28. The broker highlighted the company's robust generic drug business, which has delivered five consecutive years of profitability, with revenue reaching RMB 582 million (up 25% year-over-year) and net profit of RMB 177 million (up 30%).</p><p>Investor sentiment was further bolstered by positive updates on the company's innovation pipeline. Phase I clinical data for its novel oral drug HXP056, targeting fundus diseases, demonstrated favorable safety and tolerability, with preliminary signs of efficacy. Additionally, the company's most advanced candidate, C019199, is poised to enter Phase III clinical trials. This combination of validating broker coverage and promising pipeline catalysts supported the stock's technical rebound from a sharp decline in the previous session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1119193958","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119193958","pubTimestamp":1777428000,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"个股赛道|券商发起、财务强劲、临床数据利好海西药业盘中大涨7.66%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a target price of HKD 298.28. The broker highlighted the company's robust generic drug business, which has delivered five consecutive years of profitability, with revenue reaching RMB 582 million (up 25% year-over-year) and net profit of RMB 177 million (up 30%).Investor sentiment was further bolstered by positive updates on the company's innovation pipeline. Phase I clinical data for its novel oral drug HXP056, targeting fundus diseases, demonstrated favorable safety and tolerability, with preliminary signs of efficacy. Additionally, the company's most advanced candidate, C019199, is poised to enter Phase III clinical trials. This combination of validating broker coverage and promising pipeline catalysts supported the stock's technical rebound from a sharp decline in the previous session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119193958","isCrawlerRequest":true}